Results 231 to 240 of about 222,862 (245)
Some of the next articles are maybe not open access.

Pharmacogenetics of paclitaxel metabolism

Critical Reviews in Oncology/Hematology, 2007
Paclitaxel is one of the most widely used and effective anticancer drugs. Paclitaxel's clinical utility spans many tumor sites, including treatment of ovarian, breast, lung, head and neck, and unknown primary cancers. As is the case with most chemotherapy drugs, paclitaxel is administered empirically with little individualization of dose other than ...
Jennifer L. Spratlin, Michael B. Sawyer
openaire   +3 more sources

A facile N-debenzoylation of paclitaxel: Conversion of paclitaxel to docetaxel

Tetrahedron Letters, 1999
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Prakash Jagtap, David G. I. Kingston
openaire   +3 more sources

Pharmacology and Pharmacokinetics of Paclitaxel

Annals of Pharmacotherapy, 1994
There remain several pharmacologic considerations relating to paclitaxel that are being, or need to be, explored. Some of the more important of these include the following issues: Further elaboration of the metabolic fate of paclitaxel. A multicenter study is currently being planned to determine the complete metabolic fate of paclitaxel, using ...
openaire   +2 more sources

Thrombosis with paclitaxel

The Lancet, 1994
Sevelda, P   +4 more
openaire   +4 more sources

Paclitaxel (Taxol)

New England Journal of Medicine, 1995
E K, Rowinsky, R C, Donehower
openaire   +2 more sources

Paclitaxel

2002
Ines Mader   +5 more
openaire   +1 more source

Glaucoma and paclitaxel

The Lancet, 2000
Giovanni Rosti   +4 more
openaire   +2 more sources

Weekly paclitaxel

Critical Reviews in Oncology/Hematology, 2002
openaire   +2 more sources

Paclitaxel

2007
openaire   +1 more source

Home - About - Disclaimer - Privacy